Every dosing decision for vasoactive intestinal peptide answers to one pharmacological fact: the native 28 amino acid molecule clears from circulation in roughly one to two minutes and is destroyed outright by gastric acid and intestinal proteases, which removes oral delivery before any protocol is written. What remains is mucosal and parenteral, meaning compounded intranasal spray, nebulized inhalation, and continuous intravenous infusion of the synthetic analogue aviptadil. The honest bottom line comes first: no VIP or VIP analogue product holds United States marketing approval, so the figures that follow are study protocols and compounding conventions rather than established regimens.
VIP clears from plasma in roughly one to two minutes and is degraded by gastric acid, so the published record describes only mucosal and parenteral routes, none of which has produced a United States approved product.
The route list is short because biology eliminates most options before anyone tests them. Ordinary amide bonds leave the peptide open to pepsin in the stomach and to pancreatic and brush border proteases in the small intestine, so effectively none of an oral dose reaches circulation intact. What survives that elimination sorts by evidence strength rather than by popularity, and those two rankings run in opposite directions.
Inhaled and intravenous aviptadil hold the most rigorous trial data among VIP delivery routes while the intranasal route encountered most often in practice has the least, and the only VIP based product approved anywhere is an intracavernosal aviptadil and phentolamine combination licensed in the United Kingdom and parts of Europe, not in the United States.
A half-life measured in single digit minutes reads like a footnote and functions like a design constraint. Neutral endopeptidase, dipeptidyl peptidase IV, and mast cell derived tryptase and chymase all cut the molecule, and the lung is itself an efficient clearance organ, so an intravenous bolus produces a concentration spike largely gone before the next set of vital signs is recorded. Three consequences follow, and each explains a protocol choice that would otherwise look arbitrary.
A plasma half-life of roughly one to two minutes is why the trial protocols use twelve hour continuous infusions and local aerosol deposition rather than bolus injection, although VPAC1 and VPAC2 signaling persists after the peptide itself has cleared.
The intranasal regimen in widest circulation did not come from a randomized trial. It comes from a chronic inflammatory response syndrome treatment protocol, and its precision, 50 micrograms per 0.1 millilitre four times daily, is frequently mistaken for an established dose. Published support consists of a small open label case series plus before and after biomarker and imaging observations, which sits well below the evidence an approved label requires.
The widely circulated intranasal regimen of 50 micrograms per 0.1 millilitre four times daily originates in a treatment protocol supported by open label case observation rather than placebo controlled data, and no intranasal VIP product is approved by the United States Food and Drug Administration.
Two inhalation programs supply nearly everything known about nebulized VIP, and the more interesting result is not the one in the lung function data. The anatomical rationale behind both is strong: the lung expresses VPAC1 receptors at a higher density than nearly any other tissue, so an aerosol deposits the peptide on alveolar epithelium, bronchial smooth muscle, and pulmonary vascular endothelium instead of asking it to survive systemic transit.
| Criteria | Pulmonary arterial hypertension | Pulmonary sarcoidosis |
|---|---|---|
| Dose | 50 mcg four times daily (200 mcg/day) | 50 mcg nebulized four times daily |
| Duration | 24 weeks | 4 weeks |
| Design | Open label, 8 patients | Open label, uncontrolled |
| Reported signal | Pulmonary vascular resistance roughly halved by month 3; six minute walk improved | Lavage showed lower TNF alpha, higher regulatory T cell activity |
Both published inhalation programs used 50 micrograms nebulized four times daily, one across 24 weeks in eight patients with pulmonary arterial hypertension and one across four weeks in pulmonary sarcoidosis, and both were open label studies without a control arm.
The intravenous record belongs almost entirely to aviptadil, the synthetic form of the human peptide, studied in critically ill patients with respiratory failure. The protocol shape held constant across that work, and its most distinctive feature, day over day rate escalation, exists because the drug's vasodilatory potency makes a fixed opening rate hazardous in a population already close to hemodynamic failure.
Intravenous aviptadil was studied as a twelve hour continuous infusion on three consecutive days at roughly 50 to 150 picomoles per kilogram per hour with day over day escalation, and the United States Food and Drug Administration declined emergency use authorization for the product.
Nothing in the side effect profile is mysterious, which is unusual and useful. The limiting effects are the peptide's own pharmacology arriving at a higher dose than intended: cyclic AMP mediated smooth muscle relaxation lowers systemic vascular resistance, reflex tachycardia follows, and the intestinal secretion the molecule was originally characterized by shows up as loose stools or cramping. Route decides how much of that reaches the patient.
Hypotension is the dose-limiting effect of intravenous VIP, which is why critical care protocols excluded patients whose mean arterial pressure stayed below 65 millimetres of mercury on vasopressor support, and no controlled safety data exists beyond a few weeks of exposure.
Half a century of medicinal chemistry has aimed at a single target: keep the molecule intact longer without losing what makes it work. Two lines of attack developed, one on the packaging and one on the peptide sequence itself, and neither has reached a pharmacy shelf.
Every stabilizing modification carries a cost of its own, since a molecule that persists for hours instead of minutes sustains its vasodilatory effects for hours as well, and altered peptides can provoke immune responses the native 28 amino acid sequence does not.
Handling is where a correct dose quietly becomes an incorrect one. Lyophilized peptide is comparatively robust, generally kept frozen or refrigerated with desiccant and protected from light, but reconstituted material enters its most vulnerable state and carries a use window measured in days to a few weeks depending on buffer. The losses that matter most leave no visual evidence at all.
The potency, sterility, and stability window of a compounded VIP nasal spray rest entirely on the individual pharmacy's practices with no lot release testing or regulatory verification behind the label, so reported dosing figures describe intent rather than delivered dose.
Monitoring intensity tracks route almost exactly, and the route used most often outside trials carries the least verifiable monitoring behind it. What gets measured shifts along the same gradient, from hemodynamics at the bedside to cytokine profiles sampled at the site of action to marker panels drawn in an office.
A favorable shift in an inflammatory or hormonal marker panel is not by itself evidence that the peptide caused the change, and controlled trials consistently weight function and symptoms above laboratory panels when judging response.
There is a striking mismatch between how long this peptide has been studied and how long it is used. Formal exposures run from three days to 24 weeks, while ambulatory nasal protocols commonly describe continuous use past a year, with continuation decided by symptom response and marker trends rather than any predetermined endpoint.
| Criteria | Studied protocols | Ambulatory nasal use |
|---|---|---|
| Duration | 3 days (IV), 4 weeks (nebulized), 24 weeks (inhaled) | Many months, sometimes beyond a year |
| Basis for continuing | Fixed protocol endpoint | Symptom response and marker trends |
| After stopping | Hemodynamic gains faded once treatment ended | Not documented |
| Dependence | No withdrawal syndrome reported | No withdrawal syndrome reported |
Formal VIP exposures ran from three days to 24 weeks while ambulatory nasal protocols commonly continue past a year, so the safety and efficacy of that extended course is not supported by the cited studies but only left uncontradicted by them.
Educational use only. This article describes what the published scientific and clinical literature reports about Vasoactive Intestinal Peptide (VIP). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
